Evidence map›Paper›PMID 36901792›Full record

ReviewInternational journal of molecular sciences2023

The State of the Art of Molecular Fecal Investigations for

Francesca Celiberto, Giuseppe Losurdo, Maria Pricci, Bruna Girardi, Angela Marotti, Alfredo Di Leo, Enzo Ierardi

Full text readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Low-Abundance and FragmentaryBiomolecules · 2026
    Article
  2. Article
  3. Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Clinical evaluation of a novelFrontiers in cellular and infection microbiology · 2025
    Observational
  6. Antibiotics (Basel, Switzerland) · 2024
    Article
  7. Testing forJournal of clinical microbiology · 2024
    Review
  8. International journal of molecular sciences · 2023
    Review
  9. Helicobacter pylori infection.Nature reviews. Disease primers · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Francesca CelibertoSection of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.ORCID 0000-0001-6539-9153
Giuseppe LosurdoSection of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.ORCID 0000-0001-7038-3287
Maria PricciTHD SpA, 42015 Correggio, Italy.
Bruna GirardiTHD SpA, 42015 Correggio, Italy.
Angela MarottiSection of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
Alfredo Di LeoSection of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
Enzo IerardiSection of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.ORCID 0000-0001-7275-5080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new paradigm shift for the treatment of

Indexed as

Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsDrug Resistance, BacterialDrug Resistance, MicrobialHumansMicrobial Sensitivity TestsAnti-Bacterial Agentsantibiotic resistanceeradicationgenotypic resistanceHelicobacter pyloristoolstherapy

Identifiers

PMID36901792
PMCPMC10002064

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read85
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.